TABLE 2.

Pre and post-radiotherapy characteristics

	Robotic (n = 20)	Open (n = 19)	p value
Mean pre-radiation PSA (ng/mL)	12.1 ± 15.5	10.1 ± 10.9	0.545
Pre-radiation biopsy Gleason sum	n (%)	n (%)	0.155
6	3 (15%)	6 (32%)
7	10 (50%)	10 (53%)
8	2 (10%)	1 (5%)
9	4 (20%)	0
Unknown	1 (5%)	2 (11%)
Pre-radiation clinical stage			0.992
cT1	11 (55%)	12 (63.1%)
cT2	4 (20%)	4 (21%)
cT3	3 (15%)	3 (15.7%)
Unknown	2 (10%)	0
Primary therapy			0.899
EBRT or proton	13 (65%)	11 (57.8%)
Brachytherapy or brachytherapy/EBRT	7 (35%)	8 (42.1%)
Mean PSA nadir (ng/mL)	0.38 ± 0.37	0.70 ± 0.60	0.116
Mean Pre-SRALP PSA	2.5 ± 2.4	4.5 ± 3.1	0.021
Post-radiation biopsy Gleason sum	n (%)	n (%)	0.58
7	4 (20%)	8 (42.1%)
8	4 (20%)	4 (21%)
9	2 (10%)	3 (15.7%)
10	1 (5%)	0
Unknown/unable to be determined	9 (45%)	4 (21%)